Event compares recognising long COVID to push for ban on indoor smoking as next big public health challenge.

.

The Chrysos share price is up more than 50% since July. Looking under the hood, the business is making progress too.

But for clarity, after publishing this article, I will not trade these stocks prior to Wednesday next week.

Statistics from a global analysis of AI data centres and their intense electricity demand.

The ASX: ABV share price and the ASX: AIM share price both suggest the market is expecting strong growth. Is that justified?

PEXA has so much potential but the high quality parts of the business are blighted by the unprofitable parts.

.

Here’s why you should never conflate my disclosure with my recommendations.

If you’re wondering what earnings season coverage to read, this is my pick of the bunch. Plus, there’s a meditation on this August, at the end!

Fat-loss fad, or preventative medicine for a range of chronic health issues?

The Kip McGrath Education Centres FY 2025 statutory results were very weak, but Tutorfly cannot hurt KME shareholders any more.

The 4D Medical share price is up over 500% in less than two months. But is the 4DX share price overhyped?

Advanced Braking Technologies produced solid FY 2025 results, but the share price may well be getting a little ahead of itself.

Lawyers using AI to write court submissions caught out with non-existent cases and misquotes.

Lovisa Holdings Ltd (ASX: LOV) delivered another year of strong global growth in FY 2025, setting the stage for further expansion as a key competitor struggles.

IPD Group (ASX: IPG) FY25 results show falling margins and mixed revenue trends. Here’s why I will sell my IPG shares.

Why a homelessness advocacy group argues it makes sense.

Currently there are 7 buy recommendations and 5 hold recommendations.

Asset Vision could potentially reach profitability in FY 2026, but few are talking about the stock.